

Aref Al-Kali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2789503/publications.pdf>

Version: 2024-02-01

219
papers

3,020
citations

201385

27
h-index

214527

47
g-index

220
all docs

220
docs citations

220
times ranked

3955
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. <i>Leukemia</i> , 2013, 27, 1322-1327.	3.3	212
2	Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. <i>Leukemia</i> , 2013, 27, 1504-1510.	3.3	190
3	A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. <i>Cell Research</i> , 2018, 28, 1062-1076.	5.7	152
4	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. <i>Blood Advances</i> , 2018, 2, 923-932.	2.5	114
5	Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS mutant relapsed or refractory myeloid malignancies. <i>Cancer</i> , 2016, 122, 1871-1879.	2.0	113
6	Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. <i>Leukemia</i> , 2021, 35, 3542-3550.	3.3	97
7	Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>JAMA Oncology</i> , 2017, 3, 936.	3.4	90
8	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020, 95, 1511-1521.	2.0	83
9	Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells. <i>Leukemia</i> , 2017, 31, 1434-1442.	3.3	67
10	Clinical features and outcomes of extramedullary myeloid sarcoma in the United States: analysis using a national data set. <i>Blood Cancer Journal</i> , 2017, 7, e592-e592.	2.8	66
11	Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 673-673.	0.6	66
12	Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. <i>British Journal of Haematology</i> , 2015, 169, 77-80.	1.2	56
13	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
14	Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. <i>Blood Cancer Journal</i> , 2017, 7, e607-e607.	2.8	52
15	Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. <i>American Journal of Hematology</i> , 2019, 94, 767-779.	2.0	51
16	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018, 8, 29.	2.8	49
17	Therapy related chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML. <i>American Journal of Hematology</i> , 2018, 93, 65-73.	2.0	49
18	The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2015, 8, 114.	6.9	48

#	ARTICLE	IF	CITATIONS
19	A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis. <i>Oncotarget</i> , 2014, 5, 5494-5509.	0.8	47
20	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021, 96, 781-789.	2.0	46
21	A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target. <i>Leukemia</i> , 2018, 32, 865-873.	3.3	44
22	Vancomycin-resistant <i>Enterococcus</i> colonization and bloodstream infection: prevalence, risk factors, and the impact on early outcomes after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Transplant Infectious Disease</i> , 2016, 18, 913-920.	0.7	40
23	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015, 29, 741-744.	3.3	38
24	Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. <i>Blood</i> , 2020, 136, 909-913.	0.6	36
25	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020, 34, 656-661.	3.3	32
26	Prognostic impact of <i>RAS</i> mutations in patients with myelodysplastic syndrome. <i>American Journal of Hematology</i> , 2013, 88, 365-369.	2.0	30
27	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. <i>Blood Cancer Journal</i> , 2016, 6, e405-e405.	2.8	30
28	Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes. <i>Leukemia and Lymphoma</i> , 2017, 58, 872-881.	0.6	29
29	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021, 11, 49.	2.8	28
30	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1431-1439.	2.0	26
31	Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 6254-6266.	3.2	26
32	Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 82.	2.8	24
33	Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment. <i>Blood Cancer Journal</i> , 2016, 6, e414-e414.	2.8	23
34	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , 2017, 7, e550-e550.	2.8	21
35	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 121.	2.8	21
36	Gilteritinib clinical activity in relapsed/refractory <i>FLT3</i> mutated acute myeloid leukemia previously treated with <i>FLT3</i> inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	2.0	21

#	ARTICLE	IF	CITATIONS
37	Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 546-549.	0.2	20
38	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015, 29, 498-500.	3.3	20
39	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1363-1374.	1.4	20
40	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018, 8, 18.	2.8	19
41	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021, 5, 2272-2278.	2.5	19
42	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460.	2.0	19
43	Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. <i>Blood</i> , 2019, 134, 115-115.	0.6	19
44	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018, 71, 60-62.	0.4	18
45	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020, 33, 334-343.	2.9	18
46	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. <i>American Journal of Hematology</i> , 2017, 92, 866-871.	2.0	17
47	Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia. <i>Nature Communications</i> , 2019, 10, 5051.	5.8	17
48	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. <i>American Journal of Hematology</i> , 2022, 97, E62.	2.0	17
49	Primary Myelodysplastic Syndromes. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1623-1638.	1.4	16
50	A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome. <i>Systematic Reviews</i> , 2018, 7, 144.	2.5	15
51	Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients. <i>Haematologica</i> , 2012, 97, 235-240.	1.7	14
52	Monosomal karyotype in Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2013, 3, e122-e122.	2.8	14
53	Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. <i>International Journal of Cancer</i> , 2016, 138, 1545-1553.	2.3	14
54	ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning. <i>Transfusion</i> , 2016, 56, 518-527.	0.8	14

#	ARTICLE	IF	CITATIONS
55	Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis. <i>Oncotarget</i> , 2016, 7, 36382-36394.	0.8	14
56	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2022, 196, 975-983.	1.2	14
57	Concomitant Erdheim-Chester disease and chronic myelomonocytic leukaemia: genomic insights into a common clonal origin. <i>British Journal of Haematology</i> , 2019, 187, e51-e54.	1.2	13
58	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	13
59	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2588-2597.	0.6	12
60	HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for Leukemia. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 14454-14462.	4.0	12
61	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1467-1474.	1.4	12
62	<i>JAK2</i> wild-type erythrocytosis associated with sodium-glucose cotransporter 2 inhibitor therapy. <i>Blood</i> , 2021, 138, 2886-2889.	0.6	12
63	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. <i>Blood Cancer Journal</i> , 2021, 11, 43.	2.8	11
64	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases. <i>American Journal of Hematology</i> , 2022, 97, 630-637.	2.0	11
65	Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the <i>SARS-CoV-2</i> pandemic. <i>American Journal of Hematology</i> , 2020, 95, E203-E208.	2.0	10
66	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring <i>SF3B1</i> Mutations. <i>American Journal of Clinical Pathology</i> , 2021, 156, 679-690.	0.4	10
67	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E433-E436.	2.0	10
68	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	10
69	Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults. <i>Leukemia</i> , 2016, 30, 1177-1180.	3.3	9
70	Hypomethylating agents (HMAs) effect on myelodysplastic/myeloproliferative neoplasm unclassifiable (MDS/MPN-U): single institution experience. <i>Leukemia and Lymphoma</i> , 2018, 59, 2737-2739.	0.6	9
71	A case of ibrutinib-associated aspergillosis presenting with central nervous system, myocardial, pulmonary, intramuscular, and subcutaneous abscesses. <i>Leukemia and Lymphoma</i> , 2019, 60, 559-561.	0.6	9
72	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 990-999.	0.6	9

#	ARTICLE	IF	CITATIONS
73	<i>De novo</i> isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. British Journal of Haematology, 2021, 195, 413-416.	1.2	9
74	SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Advances, 2020, 4, 5716-5721.	2.5	9
75	DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation. Frontiers in Oncology, 2022, 12, 849376.	1.3	9
76	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. Leukemia Research, 2016, 50, 112-115.	0.4	8
77	A population-based study of chronic neutrophilic leukemia in the United States. Blood Cancer Journal, 2020, 10, 68.	2.8	8
78	Response to erythropoiesis-stimulating agents in patients with WHO-defined myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T). British Journal of Haematology, 2020, 189, e104-e108.	1.2	8
79	Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after â€˜CLAG-Mâ€™ vs. â€˜MECâ€™. Leukemia Research, 2020, 49, 106300.	0.4	8
80	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia â€˜ A Single Center Retrospective Study. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 1-9.	1.2	8
81	Prognostic impact of combined NPM1+/FLT3â€˜ genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. Leukemia Research, 2015, 39, 1207-1213.	0.4	7
82	Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2016, 57, 1714-1715.	0.6	7
83	The 2016 revised World Health Organization definition of â€˜myelodysplastic syndrome with isolated del(5q)â€™; prognostic implications of single <i>versus</i> double cytogenetic abnormalities. British Journal of Haematology, 2017, 178, 57-60.	1.2	7
84	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. Annals of Hematology, 2020, 99, 2119-2124.	0.8	7
85	Acute myeloid leukemia after age 70â€™years: A retrospective comparison of survival following treatment with intensive versus <sc>HMA</sc>â€™venetoclax chemotherapy. American Journal of Hematology, 2021, 96, E108-E111.	2.0	7
86	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer Journal, 2021, 11, 47.	2.8	7
87	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. Blood Cancer Journal, 2021, 11, 122.	2.8	7
88	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age â€™60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. Blood, 2016, 128, 339-339.	0.6	7
89	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022.	2.0	7
90	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20â€™mg twice daily or higher: A real-world experience. British Journal of Haematology, 2022, 198, .	1.2	7

#	ARTICLE	IF	CITATIONS
91	Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms. Blood Cancer Journal, 2022, 12, .	2.8	7
92	Monosomal Karyotype Predicts Adverse Prognosis in Patients Diagnosed With Chronic Myelomonocytic Leukemia: A Single-Institution Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e39-e41.	0.2	6
93	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
94	Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings, 2019, 94, 1542-1550.	1.4	6
95	A population-based study of chronic eosinophilic <scp>leukemia¬</scp> otherwise specified in the United States. American Journal of Hematology, 2020, 95, E257.	2.0	6
96	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 46.	2.8	6
97	Treatment-Related AML Patients Previously Treated with Taxanes for Breast Cancer Have Similar Outcomes As De Novo AML. Blood, 2012, 120, 3555-3555.	0.6	6
98	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (<scp>MDS&RS</scp>) but not in <scp>MDS</scp>/<scp>MPN&RS&T</scp>. American Journal of Hematology, 2022, 97, .		6
99	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. Annals of Hematology, 2019, 98, 331-337.	0.8	5
100	Classification of Monocytes, Promonocytes and Monoblasts Using Deep Neural Network Models: An Area of Unmet Need in Diagnostic Hematopathology. Journal of Clinical Medicine, 2021, 10, 2264.	1.0	5
101	Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. Blood, 2013, 122, 2745-2745.	0.6	5
102	Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease. Blood, 2016, 128, 2799-2799.	0.6	5
103	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. Blood, 2021, 138, 2158-2158.	0.6	5
104	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response. Blood Cancer Journal, 2022, 12, 7.	2.8	5
105	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Blood Cancer Journal, 2022, 12, 26.	2.8	5
106	Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget, 2017, 8, 94569-94579.	0.8	4
107	Clinical utility of fluorescence in situ hybridization-based diagnosis of <i>BCR&ABL1</i> like (<scp>P</scp>hiladelphia chromosome like) <scp>B</scp>-acute lymphoblastic leukemia. American Journal of Hematology, 2020, 95, E68-E72.	2.0	4
108	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	2.0	4

#	ARTICLE	IF	CITATIONS
109	Minimal Residual Disease (MRD) at Time of Complete Remission Is Commonly Detected in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years and Significantly Impacts Outcome Based on Post-Remission Treatment Strategies: Prospective Analysis of ECOG-ACRIN (E-A) E2906 Phase III Trial. <i>Blood</i> , 2018, 132, 437-437.	0.6	4
110	A Phase 1 Study of Lenzilumab, a humanized recombinant Anti-Human Granulocyte-Macrophage Colony-Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2019, 134, 4234-4234.	0.6	4
111	Gene Expression Profiling Identifies Distinct Signatures for Dysplastic and Proliferative Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2016, 128, 110-110.	0.6	4
112	Erythrocytosis associated with <i>EPAS1</i> , <i>HIF2A</i> , <i>EGLN1</i> , <i>PHD2</i> , <i>VHL</i> , <i>EPOR</i> , or <i>BPGM</i> mutations: The Mayo Clinic experience. <i>Haematologica</i> , 2022, 107, 1201-1204.	1.7	4
113	Isolated anemia in patients with large granular lymphocytic leukemia (LGL). <i>Blood Cancer Journal</i> , 2022, 12, 30.	2.8	4
114	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with $\alpha\text{-}7+3$. <i>Blood Cancer Journal</i> , 2022, 12, 55.	2.8	4
115	Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1582-1587.	2.0	3
116	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017, 92, E626-E627.	2.0	3
117	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and <i>FLT3</i> mutational status. <i>American Journal of Hematology</i> , 2018, 93, E401-E404.	2.0	3
118	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019, 60, 2483-2487.	0.6	3
119	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 199-204.	0.6	3
120	Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding. <i>Blood</i> , 2012, 120, 4930-4930.	0.6	3
121	Patients with Therapy-Related Myelodysplastic Syndromes (t-MDS) Have Shorter Median Overall Survival Than De Novo MDS: Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 5234-5234.	0.6	3
122	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , 2015, 126, 55-55.	0.6	3
123	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 219-219.	0.6	3
124	<i>SF3B1</i> -mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity. <i>Haematologica</i> , 2022, 107, 1189-1192.	1.7	3
125	Busulfan Treatment for Myeloproliferative Disease may Reduce Injection Burden in Vascular Endothelial Growth Factor-Driven Retinopathy. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101554.	0.4	3
126	Leukemic Polyradiculopathy Due to Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>JAMA Neurology</i> , 2015, 72, 938.	4.5	2

#	ARTICLE	IF	CITATIONS
127	Pre- β -anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E144-E146.	2.0	2
128	Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 229-232.	0.6	2
129	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357.	2.0	2
130	Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. <i>Anticancer Research</i> , 2020, 40, 3883-3888.	0.5	2
131	Pregnancy in patients with myelofibrosis: Mayo's "Florence series of 24 pregnancies in 16 women. <i>British Journal of Haematology</i> , 2021, 195, 133-137.	1.2	2
132	SF3B1 Mutations Are Prevalent in Myelodysplastic Syndromes with Ring Sideroblasts but Do Not Hold Independent Prognostic Value. <i>Blood</i> , 2011, 118, 460-460.	0.6	2
133	Comparative Analysis of Azacitidine and Decitabine in Myelodysplastic Syndromes: A Systematic Review and Network Meta-Analysis. <i>Blood</i> , 2015, 126, 1692-1692.	0.6	2
134	Safety and Tolerability of Lurbinectedin (PM01183) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2018, 132, 2722-2722.	0.6	2
135	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i> : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , 2021, 138, 3693-3693.	0.6	2
136	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401.	2.0	1
137	An Erythrocytosis-Associated Mutation in the Zinc Finger of PHD2 Provides Insights into Its Binding of p23. <i>Hypoxia (Auckland, N Z)</i> , 2019, Volume 7, 81-86.	1.9	1
138	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248.	1.2	1
139	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020, 99, 513-518.	0.8	1
140	Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 4560-4560.	0.6	1
141	Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30). <i>Blood</i> , 2019, 134, 3015-3015.	0.6	1
142	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	0.6	1
143	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	0.6	1
144	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013, 122, 4049-4049.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Clinical Outcome of Patients Diagnosed with Myelodysplastic Syndrome-Unclassifiable (MDS-U): Single Center Experience. <i>Blood</i> , 2014, 124, 3264-3264.	0.6	1
146	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012, 120, 1476-1476.	0.6	1
147	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 3873-3873.	0.6	1
148	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2013, 122, 1334-1334.	0.6	1
149	The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia. <i>Blood</i> , 2018, 132, 5440-5440.	0.6	1
150	Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T). <i>Blood</i> , 2019, 134, 4182-4182.	0.6	1
151	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019, 134, 3863-3863.	0.6	1
152	The Inspire Study in Higher-Risk Myelodysplastic Syndrome (HR-MDS): A Novel Phase 3 Study Adaptive Design for Hematological Malignancies in Adults. <i>Blood</i> , 2019, 134, 4249-4249.	0.6	1
153	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021, 138, 3657-3657.	0.6	1
154	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021, 138, 3368-3368.	0.6	1
155	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 3691-3691.	0.6	1
156	Mutational Landscape of MDS Patients with HMA Failure Revealed By the Correlative Analysis from Inspire Trial. <i>Blood</i> , 2021, 138, 1517-1517.	0.6	1
157	Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitors. <i>Blood</i> , 2020, 136, 5-7.	0.6	1
158	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
159	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients. <i>Blood Cancer Journal</i> , 2022, 12, 12.	2.8	1
160	Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia. <i>Leukemia</i> , 2022, 36, 1693-1696.	3.3	1
161	Deep neural network for cell type differentiation in myelodysplastic syndrome diagnosis performs similarly when trained on compensated or uncompensated data. , 2022, , .		1
162	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	1

#	ARTICLE	IF	CITATIONS
163	Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy. <i>International Journal of Hematology</i> , 2016, 103, 409-415.	0.7	0
164	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 246-249.	0.6	0
165	In reply to "Myelodysplastic Syndrome Over Time. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2594.	1.4	0
166	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes. <i>Blood</i> , 2011, 118, 3795-3795.	0.6	0
167	Transferrin Saturation (TS) Is a Surrogate Marker for Iron Deficiency Anemia (IDA). <i>Blood</i> , 2011, 118, 3175-3175.	0.6	0
168	FLT3 Mutation Predicts Worse Clinical Outcome of Relapsed Acute Myeloid Leukemia (rAML) Patients (Pts): Mayo Clinic Experience. <i>Blood</i> , 2012, 120, 2525-2525.	0.6	0
169	Loss of the Y Chromosome Predicts Lower Complete Cytogenetic Remission Rate in Patients (pts) with Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2012, 120, 4804-4804.	0.6	0
170	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. <i>Blood</i> , 2013, 122, 1405-1405.	0.6	0
171	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013, 122, 4048-4048.	0.6	0
172	Cytogenetic Abnormalities Predict Clinical Outcome In Patients Diagnosed With Relapsed Acute Myeloid Leukemia (rAML): Single Center Experience. <i>Blood</i> , 2013, 122, 4955-4955.	0.6	0
173	A Novel Prognostic Model To Predict Relapse After Allogeneic Stem Cell Transplantation For Myelodysplastic Syndromes. <i>Blood</i> , 2013, 122, 2098-2098.	0.6	0
174	Correlation Of Outcomes Of Allogeneic Stem Cell Transplants For Chronic Myelomonocytic Leukemia With The Mayo Prognostic Model. <i>Blood</i> , 2013, 122, 5226-5226.	0.6	0
175	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013, 122, 5000-5000.	0.6	0
176	A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TASigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results. <i>Blood</i> , 2015, 126, 3808-3808.	0.6	0
177	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. <i>Blood</i> , 2015, 126, 3730-3730.	0.6	0
178	Impact of the Type of Treatment Facility on the Outcome of Acute Myeloid Leukemia in the Adolescents and Young Adults: A National Cancer Data Base (NCDB) Study from 2003-2011. <i>Blood</i> , 2015, 126, 529-529.	0.6	0
179	Response to Hypomethylating Agents in Myelodysplastic Syndromes Based on WHO 2008 Subtypes and IPSS-R Stratification and Impact on Survival. <i>Blood</i> , 2015, 126, 5260-5260.	0.6	0
180	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015, 126, 4062-4062.	0.6	0

#	ARTICLE	IF	CITATIONS
181	Myelodysplastic Syndromes and Acute Myelogenous Leukemia Resulting from Therapy for Autoimmune Disease, a Case-Control Cohort Study. Blood, 2015, 126, 5636-5636.	0.6	0
182	Clinical Characteristics and Outcome of Adult Acute Erythroleukemia; Mayo Clinic Experience. Blood, 2015, 126, 4980-4980.	0.6	0
183	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. Blood, 2015, 126, 2490-2490.	0.6	0
184	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	0.6	0
185	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. Blood, 2015, 126, 2875-2875.	0.6	0
186	Clinical Outcome of Therapy-Related Acute Myeloid Leukemia Is Strongly Related to Cytogenetic Analysis. Blood, 2015, 126, 1401-1401.	0.6	0
187	Early CMV Infection Detected By Quantitative Nucleic Acid Testing (QNAT) Is Associated with Lower Risk of Relapse after Reduced Intensity, but Not Myeloablative, Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Blood, 2015, 126, 1913-1913.	0.6	0
188	Disparity in the Overall Survival Improvement over Time and the Effect Time-to-Treatment on the Outcome of Acute Promyelocytic Leukemia: A US National Cancer Data Base Study from 1998-2011. Blood, 2015, 126, 3747-3747.	0.6	0
189	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. Blood, 2015, 126, 4993-4993.	0.6	0
190	Clinical Outcome of Hypomethylating Agents in Hypocellular MDS: Mayo Clinic Experience. Blood, 2015, 126, 5254-5254.	0.6	0
191	The Role of Spleen Directed Therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Primary Myelofibrosis and Splenomegaly. Blood, 2015, 126, 4370-4370.	0.6	0
192	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. Blood, 2016, 128, 1996-1996.	0.6	0
193	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. Blood, 2018, 132, 1443-1443.	0.6	0
194	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. Blood, 2018, 132, 5510-5510.	0.6	0
195	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood, 2018, 132, 3268-3268.	0.6	0
196	Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia. Blood, 2018, 132, 4344-4344.	0.6	0
197	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. Blood, 2018, 132, 2658-2658.	0.6	0
198	Efficacy of Mitoxantrone-Based Salvage Therapies in Relapsed or Refractory Acute Myeloid Leukemia in the Mayo Clinic Cancer Center: Analysis of Survival after CLAG-M Vs. MEC. Blood, 2018, 132, 2678-2678.	0.6	0

#	ARTICLE	IF	CITATIONS
199	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018, 132, 2689-2689.	0.6	0
200	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019, 134, 3005-3005.	0.6	0
201	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019, 134, 5441-5441.	0.6	0
202	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019, 134, 5406-5406.	0.6	0
203	DNA Cytosine-Demethylating Agent 5-Aza-2'-Deoxycytidine Targets Leukemia Cells through Reducing DNA N6-Methyladenine. <i>Blood</i> , 2019, 134, 2513-2513.	0.6	0
204	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019, 134, 1710-1710.	0.6	0
205	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. <i>Blood</i> , 2021, 138, 3688-3688.	0.6	0
206	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , 2021, 138, 36-36.	0.6	0
207	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021, 138, 1267-1267.	0.6	0
208	Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021, 138, 2592-2592.	0.6	0
209	Differential Prognostic Impact of IDH1 and IDH2 Mutations in Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2021, 138, 3684-3684.	0.6	0
210	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021, 138, 1096-1096.	0.6	0
211	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. <i>Blood</i> , 2020, 136, 44-44.	0.6	0
212	Spectrum of Hematological Malignancies in 130 Patients with Germline Predisposition Syndromes - Mayo Clinic Germline Predisposition Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
213	IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience. <i>Blood</i> , 2020, 136, 43-44.	0.6	0
214	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020, 136, 35-36.	0.6	0
215	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020, 136, 30-31.	0.6	0
216	Characteristics and prognosis of mutated <i>STAG2</i> myeloid neoplasms. <i>Journal of Clinical Oncology</i> , 2022, 40, e19014-e19014.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	0.8	0
218	Characteristics and prognosis of <i>DDX41</i>- and <i>GATA2</i>-mutated myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19010-e19010.	0.8	0
219	Racial disparities in patients with <i>TP53</i> mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2022, 40, e19007-e19007.	0.8	0